{"product_id":"coopercos-bcg-matrix","title":"Cooper Companies Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Cooper Companies’ products sit—Stars, Cash Cows, Dogs, or Question Marks? Our BCG Matrix preview gives you the headline view, but the full report maps each product to a quadrant with data-backed reasoning. Buy the complete BCG Matrix for quadrant-by-quadrant strategy, actionable recommendations, and ready-to-use Word and Excel files. It’s the fastest way to decide where to invest, divest, or double down.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDaily silicone hydrogel dailies (MyDay, clariti 1 day)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDaily silicone hydrogel dailies (MyDay, clariti 1 day) sit in CooperCompanies' BCG Stars: high growth, high share — the sweet spot. Consumers keep trading up to dailies; CooperVision, a top-3 global player, leverages breadth and scale to capture this trend, contributing to CooperCompanies' FY2024 net sales of $1.78 billion. Continued push on retail partnerships, fitters, and direct programs is essential; keep feeding it and these investments keep paying back.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eToric portfolios (Biofinity toric, MyDay toric)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eToric portfolios Biofinity toric and MyDay toric address a growing, harder-to-serve astigmatism segment where Cooper’s extensive SKU range and proprietary fit data enable broad coverage and better first-fit success. Strong practitioner trust drives outsized share and recurring revenue from replacement cycles and loyal fittings. Despite ongoing needs for education and chair time—keeping promotional spend continuous—the incremental returns from high retention and premium pricing justify the investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultifocal dailies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePresbyopia affects over 1 billion people worldwide, and many are shifting to premium options; daily multifocals uniquely combine convenience and superior vision to capture that demand. Cooper’s broad multifocal SKU set and strong ECP fitting support drive higher adoption and reported fitting success, giving it a clear commercial edge. Market growth is brisk with dailies now representing the largest soft‑lens segment, margins remain healthy, and market leadership is within reach—priority: keep investing in awareness and fitting tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMiSight myopia management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMiSight is a Stars asset for CooperCompanies: FDA-cleared in 2019 with pivotal 3-year RCT showing ~59% reduction in myopia progression; global myopia is projected to affect ~50% of people by 2050, creating structural growth. Parent-friendly positioning and clinical proof unlock adoption curves, but heavy education, practice enablement and access work are required; potential to become category-defining.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical proof: ~59% slowing (3-yr RCT)\u003c\/li\u003e\n\u003cli\u003eRegulatory: FDA clearance 2019\u003c\/li\u003e\n\u003cli\u003eGo-to-market: education, practice enablement, access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty eye care (scleral\/ortho-k platforms)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooper’s specialty eye-care (scleral\/ortho-k) is a niche but accelerating Stars segment driven by rising myopia interest and complex prescriptions; WHO projects myopia could affect about 50 percent of the world by 2050, reinforcing long-term demand. Cooper’s specialty portfolio and practitioner training foster strong loyalty, though fitting support and training remain resource-hungry. Momentum and clinical adoption argue for continued investment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth niche\u003c\/li\u003e\n\u003cli\u003eStrong practitioner loyalty via training\u003c\/li\u003e\n\u003cli\u003eResource-intensive fitting\/support\u003c\/li\u003e\n\u003cli\u003eStrategic priority to sustain momentum\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDailies, torics, multifocals, MiSight drive growth; FY2024 net sales \u003cstrong\u003e$1.78B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCooperCompanies' Stars: dailies, torics, multifocals, MiSight and specialty lenses drive high-growth, high-share momentum—company FY2024 net sales $1.78 billion; dailies now the largest soft‑lens segment. MiSight: FDA clearance 2019; pivotal RCT ~59% myopia slowing (3 yr). Presbyopia \u0026gt;1B affected; myopia could reach ~50% by 2050—invest in fittings, education, access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eEvidence\u003c\/th\u003e\n\u003cth\u003eKey Stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDailies\u003c\/td\u003e\n\u003ctd\u003eMarket leadership\u003c\/td\u003e\n\u003ctd\u003eLargest soft‑lens segment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiSight\u003c\/td\u003e\n\u003ctd\u003eRCT\u003c\/td\u003e\n\u003ctd\u003e~59% slowing; FDA 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePresbyopia\u003c\/td\u003e\n\u003ctd\u003eDemographic\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1B affected\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyopia\u003c\/td\u003e\n\u003ctd\u003eGlobal trend\u003c\/td\u003e\n\u003ctd\u003e~50% by 2050\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix of Cooper Companies: evaluates each product line as Stars, Cash Cows, Question Marks, or Dogs with strategic investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Cooper Companies BCG Matrix highlighting cash cows and stars to speed strategic decisions and cut analysis time\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore monthly spheres (Biofinity)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCore monthly spheres Biofinity function as CooperCompanies cash cows: mature, trusted, ubiquitous product lines delivering reliable volume and strong margins; Biofinity-led lenses supported CooperCompanies' ~$3.2B 2024 revenue run-rate and constituted the majority of contact-lens sales in 2024. Low incremental promo needs and stable distribution keep incremental operating gains flowing straight to cash—maintain market leadership, avoid over-engineering.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy silicone hydrogel monthlies (non-premium tiers)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy silicone hydrogel monthlies (non-premium tiers) benefit from stable 30-day replacement cycles and predictable demand; CooperVision held roughly 10% of the global soft lens market in 2024, making volume and fulfillment key. With price points largely set, operational efficiency beats hype: focus on manufacturing yield and logistics to protect low-margin volume. Minimal marketing, prioritize supply reliability and milk gently while defending major retail and practitioner accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eParagard IUD (CooperSurgical)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eParagard IUD (approved in 1984) is a mature contraceptive brand with durable demand and established physician channels, reducing selling friction and repeat-prescription flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOB\/GYN disposables and office consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOB\/GYN disposables and office consumables are classic cash cows for Cooper Companies: recurring, sticky usage in routine procedures with predictable reorder cadence and high gross-to-net clarity; market stability in 2024 shows procedure-driven demand remaining flat-to-up 1–3% year over year. Minimal new-product lift required—focus on service, availability and procurement optimization to keep churn near zero.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue: procedure-driven, high retention\u003c\/li\u003e\n\u003cli\u003eMargin clarity: predictable gross-to-net\u003c\/li\u003e\n\u003cli\u003eOps focus: procurement programs, inventory availability\u003c\/li\u003e\n\u003cli\u003eChurn target: near 0 with service-led model\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFertility lab consumables (established accounts)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFertility lab consumables are embedded in IVF workflows with high switching costs, capturing steady replacement demand even as global IVF cycles hover around 3 million\/year (2024); operational excellence, not new features, typically delivers the largest margin gains (100–300 basis points) in established accounts. Protect contracts and harvest predictable cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh retention: contract lock-ins\u003c\/li\u003e\n\u003cli\u003eSteady replace: ~3M cycles\/yr (2024)\u003c\/li\u003e\n\u003cli\u003eMargin lever: ops \u0026gt; R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eStrategy: defend contracts, maximize cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMonthly lenses drive \u0026gt;$3B run-rate; procedure products steady; ops focus on supply \u0026amp; margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiofinity and legacy monthlies drove Cooper Companies' cash generation in 2024 (Biofinity-led contact-lens revenue supporting a ~3.2B USD run‑rate; CooperVision ≈10% of global soft-lens market), Paragard and OB\/GYN disposables showed stable procedure-driven demand (+1–3% 2024), fertility consumables tied to ~3M IVF cycles\/yr. Priorities: supply, contracts, margin via ops.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiofinity\u003c\/td\u003e\n\u003ctd\u003e~3.2B run‑rate\u003c\/td\u003e\n\u003ctd\u003emarket leadership, supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy monthlies\u003c\/td\u003e\n\u003ctd\u003eCooperVision ≈10% market\u003c\/td\u003e\n\u003ctd\u003eops efficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eParagard\u003c\/td\u003e\n\u003ctd\u003eMature Rx\u003c\/td\u003e\n\u003ctd\u003ephysician channels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOB\/GYN disposables\u003c\/td\u003e\n\u003ctd\u003e+1–3% yr\u003c\/td\u003e\n\u003ctd\u003eavailability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFertility consumables\u003c\/td\u003e\n\u003ctd\u003e~3M IVF cycles\/yr\u003c\/td\u003e\n\u003ctd\u003econtract defense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eCooper Companies BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final Cooper Companies BCG Matrix report you'll receive after purchase. No watermarks, no demo content—just the fully formatted, analysis-ready document designed for strategic clarity. Once bought, the exact same file is yours to download, edit, print, or present. Delivered immediately, it’s ready to plug into your planning with zero surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy hydrogel monthlies (non-silicone)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy hydrogel monthlies (non-silicone) are low-growth dogs: CooperCompanies reported FY2024 revenue of about $3.2 billion while contact lens mix shifts and price erosion left hydrogel monthlies with mid-single-digit share declines year-over-year. Patient and ECP migration to silicone hydrogels and dailies keeps pressure; margins are near break-even after overhead. Sunset or bundle where it aids retention, otherwise prune.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-end private-label lenses in price-war channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLow-end private-label lenses in price-war channels are commoditized, margin-thin, and loyalty-light, forcing Cooper to compete on pennies rather than differentiated value. These SKUs tie up working capital with limited strategic upside and higher inventory churn. Consider exit or strict SKU rationalization to redeploy capital to higher-margin CooperVision products and clinical innovations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-differentiated surgical instruments (crowded categories)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMe-too surgical hardware in crowded categories is squeezed by group purchasing organizations that account for over 80% of US hospital supply buying, leaving little room to raise prices or craft a differentiated story. Cash-trap dynamics appear as inventory days often run 90–120 days while slow-moving SKUs and limited returnability tie up working capital. Strategy should favor divestiture or consolidation into a few scale winners to restore margins and free cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic tail SKUs with regulatory drag\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeographic tail SKUs with regulatory drag consume disproportionate compliance overhead and operational attention for negligible revenue contribution; in 2024 CooperCompanies’ global portfolio showed a clear long tail where small markets drive tiny volumes and heavy local certification costs. They distract ops and sales, are hard to scale and harder to defend; trim and redeploy resources to core regions to improve ROI.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: low-revenue, high-compliance\u003c\/li\u003e\n\u003cli\u003eTag: operational distraction\u003c\/li\u003e\n\u003cli\u003eTag: poor scalability\u003c\/li\u003e\n\u003cli\u003eTag: redeploy to core regions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging office\/OR accessories with low utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAging office\/OR accessories show low utilization; installed-base inertia masks weak unit economics and CooperCompanies FY2024 revenue was $3.2 billion, where accessory lines contributed low-single-digit percentage of sales and replacement cycles often exceed 5 years, flattening upsell and depressing ASPs while support costs erode margin.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled-base inertia hides weak unit economics\u003c\/li\u003e\n\u003cli\u003eReplacement cycles stretch, upsell lands flat\u003c\/li\u003e\n\u003cli\u003eSupport costs quietly erode margin\u003c\/li\u003e\n\u003cli\u003eTime to discontinue or replatform\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrim low-margin SKUs, redeploy to core - FY24 rev \u003cstrong\u003e3.2B\u003c\/strong\u003e, double down on high-margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCooperCompanies FY2024 revenue ~$3.2B; legacy hydrogel monthlies face mid-single-digit share declines as patients shift to silicone\/dailies, margins near break-even. Private-label and commoditized SKUs are margin-thin; surgical me-too hardware squeezed by GPOs (\u0026gt;80% US hospital buying) with 90–120 inventory days. Trim, divest, redeploy to core high-margin products.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog type\u003c\/th\u003e\n\u003cth\u003eFY2024 metric\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHydrogel monthlies\u003c\/td\u003e\n\u003ctd\u003emid- single-digit share decline\u003c\/td\u003e\n\u003ctd\u003esunset\/bundle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate-label\u003c\/td\u003e\n\u003ctd\u003emargin-thin\u003c\/td\u003e\n\u003ctd\u003eSKU rationalize\/exit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital fitting\/remote care tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDigital fitting and remote care usage is rising and, per McKinsey, telehealth stabilized around 7% of US outpatient visits by 2024, but Cooper’s share and monetization in this space remain fuzzy. These tools could unlock practitioner efficiency and drive patient\/provider lock-in if integrated with Cooper’s device portfolio. Realizing value requires investment in UX, EHR\/EMR integrations, and clinical proof points. If adoption sticks, this question mark can graduate rapidly to a star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic testing and analytics in fertility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenetic testing and analytics in fertility sit in a high-growth segment—industry estimates show reproductive genetics\/PGT markets growing at ~10–12% CAGR into 2030—yet adoption is early, with PGT used in roughly 20–30% of IVF cycles in major markets. Competition is fragmented and guidelines are evolving, creating room for differentiation and outcome claims but requiring heavy capital and clinical validation. Cooper should bet selectively where a data advantage and clinical evidence can drive share and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium dailies expansion in emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket growth for premium daily disposables in emerging markets is strong, driven by rising refractive surgery avoidance and hygiene preferences; Cooper’s market share varies widely by country, from low-penetration positions to competitive mid-market standing. Access, pricing and local distribution or OEM partnerships determine trajectory and uptake. Upfront spend in clinician education, registration and supply-chain setup is non-trivial; scale rapidly or pivot to core tiers to protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-gen minimally invasive gyne solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNext-gen minimally invasive gyne solutions show an attractive outcomes story with potential to reduce LOS and complications; CooperCompanies reported fiscal 2024 revenue of ~$1.87B, positioning it to invest selectively. However pipelines are crowded (\u0026gt;30 competing assets in 2024 evaluations) and hospital adoption remains slow (typical 18–24 month cycles), evidence- and KOL-driven.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: targeted clinical\/KOL programs\u003c\/li\u003e\n\u003cli\u003ePayer clarity: prioritize markets with defined CPT\/DRG paths\u003c\/li\u003e\n\u003cli\u003eInvest where real-world evidence can be generated within 12–18 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrtho-k ecosystems and myopia services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrtho-k is a Question Mark for Cooper: rapid patient interest and a fragmented standards landscape meet uneven practitioner readiness, with global myopia prevalence ~34% in 2024 and projections toward 50% by 2050 driving demand.\u003c\/p\u003e\n\u003cp\u003eOrtho-k could complement MiSight to broaden Cooper’s care stack, but training and supply-chain logistics are choke points; invest in regions with dense fitters or exit if customer acquisition cost remains prohibitive.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003erapid interest\u003c\/li\u003e\n\u003cli\u003efragmented standards\u003c\/li\u003e\n\u003cli\u003euneven practitioner readiness\u003c\/li\u003e\n\u003cli\u003ecomplements MiSight\u003c\/li\u003e\n\u003cli\u003etraining \u0026amp; logistics choke points\u003c\/li\u003e\n\u003cli\u003einvest where fitters dense \/ pull back if CAC high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrioritize reimbursed markets with fast RWE: telehealth, PGT, myopia upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDigital fitting\/telehealth (~7% US outpatient visits by 2024) and PGT (10–12% CAGR to 2030) are high-growth but early for Cooper; premium daily disposables and ortho-k face strong regional upside vs. execution\/education costs; next-gen gyn requires heavy evidence spend despite Cooper’s $1.87B FY2024 base. Prioritize markets with clear reimbursement and fast real-world evidence timelines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooper FY2024 rev\u003c\/td\u003e\n\u003ctd\u003e$1.87B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth share (US)\u003c\/td\u003e\n\u003ctd\u003e~7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePGT CAGR\u003c\/td\u003e\n\u003ctd\u003e10–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal myopia 2024\u003c\/td\u003e\n\u003ctd\u003e~34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098002723164,"sku":"coopercos-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/coopercos-bcg-matrix.png?v=1781791627","url":"https:\/\/pestel-analysis.com\/products\/coopercos-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}